ÖZET
Çölyak hastalığı insanlarda en sık görülen otoimmun karakterli ve
besin kökenli bir ince barsak hastalığıdır. Son yıllarda serolojik tarama
metodlarının tespiti, genetik ve moleküler gelişmeler neticesinde
hastalığın düşünülenden çok daha sık görüldüğü anlaşılmıştır.
Daha önce yapılan çalışmalarda tip 1 diabetes mellitus, otoimmun
tiroiditis, irritabl barsak sendromu olan hastalarda çölyak hastalığı
normal popülasyona göre artmış olarak bulunmuş ve bu hastalarda
tarama yapılması gerekliliği belirtilmiştir. Yine idiopatik transaminaz
yüksekliği, gelişme geriliği, gecikmiş puberte, infertilite, demir eksikliği
anemisi, dental enamel kayıplarında, otoimmun endokrinopatiler,
osteoporozlu hastalar ve çölyak hastalarının birinci ve ikinci derece
akrabalarında da çölyak hastalığının taranmasının gerekliliği
bildirilmiştir.
Vitiligo epidermiste melanosit kaybına bağlı olarak gelişen beyaz
renkli yama tarzında maküler lezyonlarla karakterize depigmentasyonla
seyreden otoimmun bir hastalıktır. Yine daha önce yapılan çalışmalarda
vitiligo hastalarında alopesi areata, diabetes mellitus, pernisyöz anemi,
Addison hastalığı, Hashimato tiroditi ve otoimmun tirodit sıklığının
arttığı ve normal popülasyondan daha sık görüldüğü belirtilmiştir.
Biz bu çalışmamızda vitiligo hastalığının çölyak hastalığı ile
ilişkisini araştırdık. Çalışmaya klinik olarak vitiligo tanısı konan 33
kadın 48 erkek toplam 81 hasta alındı. Sağlıklı hastane personeli ve
hastaların sağlıklı yakınlarından oluşan yaş ve cinsiyeti hasta grubu ile
uyumlu 37 kadın ve 51 erkekten oluşan toplam 88 kişilik kontrol grubu
oluşturuldu. Her iki grupta da IgA EMA ve IgA tTG antikorları
61
araştırıldı. Çalışma grubundan bir olguda IgA EMA ve IgA tTG
antikorları pozitif bulunurken, kontrol grubundan bir olguda ise IgA
EMA pozitif saptanırken aynı olguda IgA tTG şüpheli pozitif saptandı.
Her iki olguya da gastroduodenoskopi ve ince barsak biyopsisi yapıldı.
Çalışma grubundan alınan biopsi sonucu çölyak hastalığı tespit
edilirken , kontrol grubundan alınan biopsi sonucu normal duodenum
mukozası olarak değerlendirildi.
İki grup arasında istatiksel olarak anlamlı bir farklılık saptanmadı
(p>0,05).
Bu bulguların eşliğinde daha önce yapılan bir çalışmaya paralel
olarak vitiligo hastalarında çölyak hastalığının sık görülmediğini
saptadık. Vitiligo hastalarında çölyak hastalığı serolojik testlerinin rutin
olarak kullanılmasının gerekli olmadığının kanaatine vardık.
62
KAYNAKLAR
1.
Katia O, Nanny VG, Jean-Marie N. Evidence for an Autoimmune
Pathogenesis of Vitiligo. Pigment Cell Res 2003;16:90-100
2.
Ortanne JP. Vitiligo and Other Disorder of Hypopigmentation. İn
Bolognia Jorizzo JL, Rapini RP, EDS. Dermatology. 1 st ed.
Philadelphia: Elsevier;2004. P :947-973
3.
Kemp EH, Wateman EA, Hawes BE, et al: The melanocortin
receptor 1, a novel target of autoantibody responses in vitiligo
2002. J Clin İnvest 2002; 109: 923-30
4. Nijoo MD, Spuls PI, Bos JD, Westerhof W, Bossuyt PM.
Nonsurgical repigmentation therapies in vitiligo: meta-analysis of
the literature. Arch Dermatol 1998; 134: 1532-40
5.
Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvares MB,
Ortiz CA, Torres-Rubulcava AB. A double-blind randomized trial
of 0.1 % tacrolismus vs 0.05 clobetasol fort he treatment of
childhood vitiligo. Arch Dermatol 2003; 139:581-5.
6.
Kovacs SO. Vitiligo. J Am Acad Dermatol 1998; 38: 647-66
7.
Schwartz RA, Janniger CK: Vitiligo. Cutis 1997; 60: 239-44
8. Trier J. Celiac Sprue and Refractory sprue. In : Feldman M,
Scharschmidt BF, Sleissenger MH. Gastrointestinal and Liver
Disease. 7th. Ed., Philadelphia: Saunders Co, 2000; 1817-41
9.
Feighery C, Coeliac disease-klinical review. BMJ 1999; 319: 236-
39
10. Lee SK, Lo W, Memeo L, et al. Duodenal histology in patients
with celiac disease after treatment with a gluten-free diet.
Gastrointes Endoscopy. 2003; 57 :187-91
63
11. Colombel J, Mascart-Lemone F, et al. Jejunal immuno-globulin and
antigliadin antihodv secretion in adult coeliac disease. Gut 1990:
31; 1341-45
12. Green PH, Jabri B. Coeliac disease. Lancet 2003; 362: 383-91
13. Madara J, Trier J, Strutural abnormalities of jejunal epithelial cell
membranes in celiac sprue. Lab Invest 1980; 243-54
14. Gillet HR, Arnott ID, Mc Intyre M, et al. Successful infliximab
treatment for steroid-refractory celiac disease: a case report.
Gastroenterology 2002; 122:800-5
15. Archer TP, Burgun j, Frankel WL, et al. A pruritic skin rash
followed by chronic diarrhea. Hosp Pract 1999; 34: 125-132
16. Poon E, Nixon R. Sings, syndromes and diagnoses. Cutaneous
spectrum of celiac disease. Aust J Dermatol 2001; 42: 136-41
17. Bottaro G, Cataldo F, Rotolo N, et al. The clinical pattern of
subclinical/silent celiac disease: an analysis on 1026 consecutive
cases. Am J Gastroenterol 1999; 94: 691-96
18. Montalto M, Diociaiuti A, Alvaro G, et al. Atypical mole syndrome
and congenital giant naevus in a patient with celiac disease.
Panminevara Med 2003; 45: 219-21
19.
Farell RJ., Kelly CP., Diagnosis of Celiac Sprue. Am J
Gastroenterol 2001; 96: 3237-46
20. Abdulkarim AS, Murray JA. Review article: the diagnosis of
coeliac disease. Aliment Pharmacol 2003; 17: 987-95
21.
King AL, Ciclitara PJ. Celiac disease: strongly heritable,
oligogenic, but genetically complex. Mol Genet Metab 2000; 71:
70-5
22. Ün C, Aydoğdu S. Çölyak hastalığının moleküler genetik temelleri.
Çocuk Sağlığı ve Hastalıkları Dergisi 2003; 46: 75-79
64
23. Catalado F, Montalto G. Celiac disease in the developing countries:
A new and challenging public health problem. World Journal of
Gastroenterology 2007; 13(15): 2153-59
24. Gee S. On the coeliac affection. St Bath’ s Hosp Rep 1888; 24: 17-
20
25. Dicke WK, Weijers HA et al. Coeliac Disease 2. The presence in
wheat of a factor having a deletorious effect in cases of coeliac
disease. Acta Pediatr 1953; 42: 34-42
26. Paulley L. Observations on the aethiology of idiopathic steatorreha.
BMJ 1954; 2:1318-21
27. Howell MD, Aurtın RK, Kelleher D, et al. An HLA-D region
restriction fragment length polimorphism associated with celiac
disease. J Exp Med 1986; 164:133.
28. Logan RF, Tucker G, Rifkind RA. Et al. Changes in clinical figures
of coeliac disease in adults in Edinburgh and the Lothians 1960-79.
Br Med J 1983; 286: 95
29. Fasano A. Where all the American celiacs gone? Acta Paediatr
suppl 1996; 412: 20-4
30. West J, Lloyd CA, Reader R, Hill PG et al. Prevalance of
undiagnosed coeliac disease in general population of England. Gut
2001; 48(suppl 1): A237
31. Ivarsson A, Persson LA, Juto P, Peltonen et al. High prevalance of
undiagnosed coeliac disease in adults: a Swedish populatıon based
study J Intern Med 1999; 245: 63-8.
32. Farrell RJ, Kelly CP. Celiac sprue and refractory sprue. Sleisenger
and Fordtran’s Gastrointestinal and Liver Disease 7th Edition.
2002; 1817-42
65
33. Not T, Horvath K,Hill ID, Partanen J et al. Coeliac disease risk in
the USA: high prevalance of antiendomysium antibodies in healthy
blood donors. Scand J Gastroenterol 1998; 33: 494-8
34. Volta U, Bellentani S, Bianchi FB, et al. High prevalance of celiac
disease in İtalian general population. Dig Dis Sci 2001; 46: 1500-5
35. Weile B, Cavell B, Nivenius K, et al. Striking differences in the
incidence of childhood celiac disease between. Denmark and
Sweden: A plausible explanation. J Pediatr Gastroenterol Nutr
1995; 21: 64-8
36. Elsürer R, Tatar G, Şimşek H, et al. Celiac disease in the Turkısh
Population. Dig Dis Sci. 2005; 50: 136-42
37. Hansen D, Bennedbaek FN, Hansen LK,et al. High prevalance of
celiac disease in Danish children with type 1 diabetes mellitus.
Acta Paediatr 2001; 90: 1238-43
38. Not T, Tommasini A, Tonini G, Buratti E, et al. Undiagnosed
celiac disease and risk of autoimmune disorders in subjects with
Type 1 diabetes mellitus. Diabetologia 2001; 44(2): 151-5.
39. Valentino R, Savastano S, Maglio M, et al. Markers of potential
celiac disease in patients with Hashimato’s thyroiditis. Eur J
Endocrinol 2002; 146: 479-83
40. Sanders DS, Carter MJ, Huristone DP, et al. Association of adult
celiac disease with irritabl bowel syndrome: a case-control study in
patients fulfilling ROME 2 criteria referred to secondary care.
Lancet 2001; 358: 1504-8
41. Volta U, Granito A, De Franceschi L, et al. Anti tissue
transglutaminase antibodies as predictors of silent celiac disease in
patients with hypertransaminasaemia of unknown origin. Dig Liver
Dis 2001; 33: 420-25
66
42. Grieco A, Miele L, Pignotoro G, et al. Is coeliac disease a
confounding factor in the diagnosis of NASH. Gut 2001; 49:596.
43. Carroccio A, Giannitrapani L, Soresi M, et al. Guinea pig
transglutaminase immunolinked assay does not predict celiac
disease in patients with chronic liver disease. Gut 2001; 49: 506-11
44. Logan RF, Rifkind EA, Turner ID, Ferguson A. Mortality in celiac
disease: Gastroenterology 1989; 97:265-71
45. Corrao G, corrazza GR, Bagnardi V, et al. Mortality in patients
with coeliac disease and their reatives: a cohort study Lancet 2001;
358: 356-61
46. Gren PH, Fleischaur AT, Bhagat G, et al. Risk of malignancy in
patients with celiac disease. Am J Med 2003; 115: 191-5
47. Howdle PD, Jalal PK, Holmes GK, Houlston RS. Primary small-
bowel malignancy in the UK and its association with coeliac
disease. QJM 2003; 96: 345-53
48. Troncone R, Auricchio S, De Vincenzi M, et al. An analysis of
cereals that react with serum antibodies in patients with coeliac
disease. J Pediatr Gastroenterol Nutr 1987; 6: 346-50
49. Holm K, Maki M, et al. Oats in the treatment of childhood coeliac
disease: a 2-year controlled trial and a longterm clinical follow-up
study Alimentary Pharmacology & Therapeutics. 2006; 23; 1463.
50. Demir H, Yüce A. Çölyak hastalığı ve otoimmunite. Katkı Pediatri
Dergisi 2002; 23(4): 389-94
51. Neuhausen SL, Weizman Z, Camp NJ, et al. HLA DQA1-DQB1
genotypes in Bedouin families with celiac disease. Hum Immunol
2002; 63: 502-7
52. Salazar de Sauza J, Ramos de Almeida JM, Monteiro MV,
Magalhaes Ramalho P. Late onset coeliac disease in the
67
monozygotic twin of a coeliac child. Acta Paediatrica Scandinavica
1987; 76: 172-74
53. Sollid LM, Markussen G, Ek J, Gjerde H, Vartdal F, Thorsby E.
Evidence for a primary association of celiac disease to a particular
HLA-DQ alpha/beta hetrodimer. J Exp Med 1989; 169: 345-50
54. Kagnoff MF, Celiac disease: A gastrointestinal disease with
environmental genetic and immunologic components.
Gastroenterol Clin N Am 1992; 21:405-25
55. Bevan S, Popat S, Braegger CP, et al. Contribution of the MHC
region to the familial risk of coeliac disease. J Med Genet 1999; 36:
687-90
56. Branski D, Troncone R. Celiac disease: a reappraisal. J Periatr
1998; 133:181-7
57. Kagnoff M, Harwood J, Bugawan T, et al. Structural analysis of the
HLA-DR, -DQ and –DP alleles on the celiac disease-associated
HLA-DR3 (DRw17. haplotype). Proc. Natl. Acad. Sci. USA
1989;86:6274-78
58. Ferreira M, Lloyd Davies S, Butler M, et al. Endomysial antibody:
Is it the best screening test for coeliac disease? Gut:1992; 33:1633-
37
59. Feighery C, Coeliac disease- klinical review. BMJ 1999; 319:236-
39
60. Madara J, Trier J, Strutural abnormalities of jejunal epithelial cell
membranes in celiac sprue. Lab Invest 1980; 243-54
61. Goddard CJR, Gillett HR. Complications of coeliac disease: are all
patients at risk? Postgrad Med J. 2006;82: 705-712
62. Hopper AD, Hadjivassiliou M, Butt S, Sanders DS. Adult coeliac
disease. BMJ 2007 ;335: 558-562
68
63.
American Gastroenterological Association (AGA) Institute
Technical Review on the Diagnosis and Management of Celiac
Disease. Gastroenterology. 2006; 131: 1981-2002
64. Chand N, Mihas AA. Celiac Disease Current Concepts in
Diagnosis and Treatment. Journal Clinical Gastroenterology 2006;
40(1): 3-14
65. Ozaslan E, Koseoğlu T, Kayhan B. Coeliac crisis in adults: report
of two cases. Eur. J. Emerg. Med 2004; 11 : 363-365
66. Gren PHR, Stavropoulos SN, Panagi SG, et al. Characteristics of
adult celiac disease in the USA: results of a national survey. The
Amerikan Journal of Gastroenterology.2001; 96(1) :126-131
67. Farell RJ, Kelly CP. Celiac Sprue. New England Journal of
Medicine. 2002; 346:180-88
68. Loftus G, Murray A. Celiac Disease Diagnosis and Management.
Hospital Physician. 2003 ; May: 45-55
69. Robinson P, Bullen A, Hall R, et al. Splenic size and function in
adult coeliac disease. Br J Radiol. 1980; 53: 532-7
70. Scotta M, Salvatore S, Salvatoni A, et al. Bone mineralization and
body composition in young patients with celiac disease. Am J
Gastroenterol 1997; 92:1331-34
71. Fickling W, McFarlane X, Bhalla A, et al. The clinical impact of
metabolic bone disease. Postgrad Med J 2001; 77: 33-36
72. Siqueira J, Fallo D, Ritis G, et al. Neurological manifestations of
celiac disease. Arg Neuropsiquiatr. 2004 Dec; 62: 969-72
73. Otley C, Hall R, et all. Dermatitis Herpetiformis. Dermatol. Clin.
1990; 87: 59-69
69
74. Kaukinen K, Hamle L, Collin P, et al. Celiac disease in patients
with severe liver disease: gluten-free diet may reverse hepatic
failure. Gastroenterology 2002; 123: 2158-59
75. Shamir R, Advances in Celiac Disease. Gastroenterology Clinics of
North America. 2003; 32: 931-47
76. Fasano A. Clinical presentation of celiac disease in pediatric
population. Gastroenterology 2005; 128: 68-73
77. Holmes GTK. Screeing for coeliac disease in type 1 diabetes. Arch
Dis Child 2002; 87: 495-99
78. Ertekin V, Selimoğlu MA, Döneray H, Orbak Z, Özkan B.
Prevalance of celiac disease in a sample of Turkısh children and
adolescents with type 1 diabetes mellitus. J Clin Gastroenterol
2006; 40: 655-7
79. Saadah OI, Zacharin M, O’Callaghan A, et al. Effect of gluten-free
diet and on growth and diabetic control in diabetics with coeliac
disease. Arch Dis Child 2004; 89: 871-6
80. Helms S. Celiac Disease and Gluten Associated Disease. Alt Med
Rev 2005;3: 172-92
81. Larizza D, Calcaterra V, De Giacomo C, et al. Celiac disease in
children with autoimmun thyroid disease. J Pediatr 2001; 139: 738-
40
82. Book L, Hart A, Black J, et al. Prevalance and clinical
characteristics of celiac disease in Down’s Syndrome in the United
States. Clin Pediatr 2001; 40: 249-52
83.
Kansu A. Çölyak Hastalığında Güncel Gelişmeler. Turkiye
Klinikleri J Pediatr sci 2007, 3(7): 18-24
84. Rodrigo L. Celiac Disease. World Journal of Gastroenterology.
2006; 12(41):3-14
70
85. Rostami K, Kerakhaert J, et al. Sensitivity of antiendomysium and
antigliadin antibodies in untreated celiac disease: disappointing in
clinical practice. Am J Gastroenterol 1999; 94: 888-94
86. Rostrom A, Dube C, Cranney A, et al. The diagnostic accury of
serologic tests for coeliac disease: a systematic review.
Gastroenterology 2005; 128(4 suppl. 1):S38-46
87. Corrao G, Corazza GR, Andreani ML, et al. Serological screening
of coeliac disease: Choosing the optimal procedure according to
various prevalance values. Gut 1994; 35: 771-5
88. Cataldo F, Marino V, Ventura A, Bottaro G, Corazza GR.
Prevalance and clinical features of selective immunglobulin A
deficiency in coeliac disease: an Italian multicentre study. Italian
Society of Paediatric Gatroenterology and Hepatology(SIGEP) and
‘‘Club del Tenue’’ Working Groups on Coeliac Disease. Gut 1998;
115: 1322-28
89. Sategna-Guidetti C, Pulitano R, Grosso S, Ferfoglia G. Serum IgA
antiendomysium antibody titers as a marker of intestinal
involvement and diet compliance in adult celiac sprue. J Clin
Gastroenterol 1993; 17: 123-27
90. Dahale A, Kingstone K, Bode J, Anderson D, Ghosh S. Anti-
endomysial antibody negative celiac disease: does additional
serological testing help? Dig Dis Sci 2001; 46: 214-21
91. Green PH, Murray JA. Routine duodenal biopsies to exclude celiac
disease? Gastrointest Endosc 2003; 58: 92-5
92. Farell RJ, Kelly CP. Celiac sprue and Refracter Sprue. Sleisenger
and Fordtran’s Gastrointestinal and Liver Disease. 8th. adition
Saunders Elseiver Chapter 101: 2277-2306
71
93. Bhatnagar S, Tandon N. Diagnosis of Celiac Disease. Indian
Journal of Pediatrics 2006; 73(8): 703-709
94. Per Brandtzaeg. The changing immunological paradigm in coeliac
disease. Immunology Letters. 2006 ;105: 127-39
95. Ortonne JP, Bahadoran P, Fitzpatrick TB, Mosher DB, Hori Y:
Hypomelanoses and hypermelanoses. Fitzpatrick’s Dermatology in
General Medicine. Ed. Freedberg IM, Eisen AZ, Wolff K, Austen
KF, Goldsmith LA, Katz SI. 6th ed. New York, McGraw Hill,
2003; 836-881
96. Baransü O. Pigmentasyon bozuklukları. Dermatoloji. Ed. Tüzün Y,
Kotoğyan A, Aydemir EH ve ark. İstanbul, Nobel Tıp Kitabevi,
1994; 555-560
97. Braun-Falco O, Plewig G, Wolff HH, Burgdorf WHC. Disorders of
melanin pigmentation. Dermatology. Berlin, Springer Verlag,
2000; 1013- 1042
98. Spielvogel RL, Kantor GR. Pigmentary disorders of the skin.
Lever’s Histopathology of the skin. Editor in Chief, Elder D. Ed.
Elenitsas R, Jaworsky C, Johnson Jr B. Philadelphia, Lippincott
Raven, 1997; 617-623
99. Hann SK, Nordlund J. Vitiligo. Oxford, Blackwell Science, 2000.
100. Arıcan Ö, Koç K, Kutluk R, Ersoy L. Vitiligolu hastalarda serum
vitamin B12 ve folik asit düzeyleri. T Klin Dermatoloji 2003; 13:
4-10
101. Mosher DB, Fitzpatrick TB, Ortonne JP, Hori Y. Hypomelanoses
and hypermelanoses. In: Fitzpatrick TB, Eisen AZ, Wolff K,
Freedber IM, Austen AF, eds. Dermatology in General Medicine.
5th ed. New York: McGraw-Hill 1999: 945-1017
72
102. Bahadır S, Yaylı S: Çocuklarda vitiligo: Epidemiyoloji ve
Etiyoloji. 1. Ulusal Pediatrik Dermatoloji Günleri 2004; 8-16
103. Grimes PE: White patches and bruised souls: Advences in the
pathogenesis and treatment of vitiligo. J Am Acad Dermatol 2004;
51: 5-7
104. Şendur N: Çocuklarda vitiligo: Klinik. 1. Ulusal Pediatrik
Dermatoloji Günleri 2004; 17-24
105. Njoo MD, Das PK, Bos JD, Westerhof W: Association of the
koebner phenomenon with disease activity and therapeutic
responsiveness in vitiligo vulgaris. Arch Dermatol 1999; 135: 407-
413
106. Lerner AB. Vitiligo. J Invest Dermatol 1959; 32: 285-310
107. Le Pool IC, Das PK, van den Wijngaard RMJGJ, Bos JD,
Westerhof W. Review of the etiopathomecanism of vitiligo: A
convergence theory. Exp Dermatol 1993; 2: 145-53
108. Ortonne JP, Bose SK. Vitiligo: Where do we stand?. Pigment Cell
Res 1993; 2: 145-53
109. Naughton G, Eisenger M, Bystryn J. Detection of antibodies to
melanocytes in vitiligo by specific immunoprecipitation. J Invest
Dermatol 1983; 81: 540-2
110. Naughton G, Reggiardo D, Bystryn J. Correlation between vitiligo
antibodies and extent of depigmentation in vitiligo. J Am Acad
Dermatol 1986; 15: 978-81
111.
Yu J, Kao C, Yu C. Coexistence and relationship of
antikeratinocyte and antimelancyte antibodies in patients
nonsegmental-type vitiligo. J Invest Dermatol 1993; 100:823-8
112. Cui J, Arita Y, Eisinger N. Characterization of vitiligo antigens. J
Invest Dermatol 1992; 98: 600-3
73
113. Cui J, Harning R, Henn M, Brystryn JC. Identification of pigment
cell antigens defined by vitiligo antibodies. J Invest Dermatol 1992;
98: 162-5.
114. Harning R, Cui J, Bystryn J. Relation between the incidence and
level of pigment cell antibodies and disease activity in vitiligo. J
Invest Dermatol 1991; 97: 1078-80
115. Baharav E, Merimski O, Shoenfeld Y, Zigelman R, Gilbrud B,
Yecheskel G, Yıuinau P, Fishman P. Tyrosinase as an autoantigen
in patients with vitiligo. Clin Exp Immunol 1996; 105: 84-8
116. Wojdani A, Grimes P, Loeb L. Detection of antibenzene ring
antibodies in patients with vitiligo. J Invest Dermatol 1992; 98:
644-8
117. Schallreuter KU, Kühnl P, Löliger C, Hohl-Tehari M, Berger J.
Histocompatibility antigens in vitiligo: Hamburg study on 102
patients from Northern Germany. Dermatology 1993; 129: 408-10
118. Soubrian P, Benzaken S, Bellet C, Lacaur JP, Ortonne JP. Vitiligo:
Dostları ilə paylaş: |